Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

6(75.0%)

Phase 2

2(25.0%)

8Total

Phase 1(6)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04718584Phase 2Completed

the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors

Role: lead

NCT03491709Phase 1Completed

A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC

Role: lead

NCT04739111Phase 1Completed

An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor

Role: lead

NCT03908814Phase 1Completed

Phase I Clinical Trial of Human Anti-PD-L1 Antibody Injection (LDP) in Patients With Advanced Malignant Tumors

Role: lead

NCT03881787Phase 1Completed

Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux

Role: lead

NCT07447102Phase 2Recruiting

Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis

Role: lead

NCT04151810Phase 1Completed

Phase I Clinical Trial of CDP1 in Patients With Advanced Solid Tumors

Role: lead

NCT05212896Phase 1Unknown

An Exploratory Clinical Study of BC006 in Patients With Advanced Solid Tumors

Role: lead

All 8 trials loaded